The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review


Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Porphyrias


Psychiatry related information on Porphyrias


High impact information on Porphyrias


Chemical compound and disease context of Porphyrias


Biological context of Porphyrias


Anatomical context of Porphyrias


Gene context of Porphyrias


Analytical, diagnostic and therapeutic context of Porphyrias


  1. Activation of the complement system in patients with porphyrias after irradiation in vivo. Lim, H.W., Poh-Fitzpatrick, M.B., Gigli, I. J. Clin. Invest. (1984) [Pubmed]
  2. Development of porphyria cutanea tarda after treatment with cyclophosphamide. Manzione, N.C., Wolkoff, A.W., Sassa, S. Gastroenterology (1988) [Pubmed]
  3. Hepatoerythropoietic porphyria: a new uroporphyrinogen decarboxylase defect or homozygous porphyria cutanea tarda? Elder, G.H., Smith, S.G., Herrero, C., Lecha, M., Mascaro, J.M., Muniesa, A.M., Czarnecki, D.B., Brenan, J., Poulos, V., DE Salamanca, R.E. Lancet (1981) [Pubmed]
  4. The primary enzyme defect in hereditary coproporphyria. Elder, G.H., Evans, J.O., Thomas, N. Lancet (1976) [Pubmed]
  5. Is hepatitis C virus infection a trigger of porphyria cutanea tarda? Herrero, C., Vicente, A., Bruguera, M., Ercilla, M.G., Barrera, J.M., Vidal, J., Terés, J., Mascaró, J.M., Rodés, J. Lancet (1993) [Pubmed]
  6. Uroporphyria caused by ethanol in Hfe(-/-) mice as a model for porphyria cutanea tarda. Sinclair, P.R., Gorman, N., Trask, H.W., Bement, W.J., Szakacs, J.G., Elder, G.H., Balestra, D., Sinclair, J.F., Gerhard, G.S. Hepatology (2003) [Pubmed]
  7. Nutritional regulation of hepatic heme biosynthesis and porphyria through PGC-1alpha. Handschin, C., Lin, J., Rhee, J., Peyer, A.K., Chin, S., Wu, P.H., Meyer, U.A., Spiegelman, B.M. Cell (2005) [Pubmed]
  8. PGC-1alpha: looking behind the sweet treat for porphyria. Li, D. Cell (2005) [Pubmed]
  9. Mutations of the hereditary hemochromatosis candidate gene HLA-H in porphyria cutanea tarda. Santos, M., Clevers, H.C., Marx, J.J. N. Engl. J. Med. (1997) [Pubmed]
  10. Erythropoietin for the treatment of porphyria cutanea tarda in a patient on long-term hemodialysis. Anderson, K.E., Goeger, D.E., Carson, R.W., Lee, S.M., Stead, R.B. N. Engl. J. Med. (1990) [Pubmed]
  11. Treatment of hemodialysis-related porphyria cutanea tarda with deferoxamine. Praga, M., Enriquez de Salamanca, R., Andres, A., Nieto, J., Oliet, A., Perpiña, J., Morales, J.M. N. Engl. J. Med. (1987) [Pubmed]
  12. Chloroquine in the treatment of porphyria cutanea tarda. Kordac, V., Papezová, R., Semrádová, M. N. Engl. J. Med. (1977) [Pubmed]
  13. Iron deficiency prevents liver toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin. Sweeny, G.D., Jones, K.G., Cole, F.M., Basford, D., Krestynski, F. Science (1979) [Pubmed]
  14. Induction of a deficiency of steroid delta 4-5 alpha-reductase activity in liver by a porphyrinogenic drug. Kappas, A., Bradlow, H.L., Bickers, D.R., Alvares, A.P. J. Clin. Invest. (1977) [Pubmed]
  15. Risks of valproate in porphyria. Garcia-Merino, J.A., Lopez-Lozano, J.J. Lancet (1980) [Pubmed]
  16. Dual mechanism of inhibition of rat liver uroporphyrinogen decarboxylase activity by ferrous iron: its potential role in the genesis of porphyria cutanea tarda. Mukerji, S.K., Pimstone, N.R., Burns, M. Gastroenterology (1984) [Pubmed]
  17. Molecular analysis of delta-aminolevulinate dehydratase deficiency in a patient with an unusual late-onset porphyria. Akagi, R., Nishitani, C., Harigae, H., Horie, Y., Garbaczewski, L., Hassoun, A., Mercelis, R., Verstraeten, L., Sassa, S. Blood (2000) [Pubmed]
  18. Spectrum of mutations in the HFE gene implicated in haemochromatosis and porphyria. de Villiers, J.N., Hillermann, R., Loubser, L., Kotze, M.J. Hum. Mol. Genet. (1999) [Pubmed]
  19. Hepatic mitochondrial oxidative metabolism and lipid peroxidation in experimental hexachlorobenzene-induced porphyria with dietary carbonyl iron overload. Feldman, E.S., Bacon, B.R. Hepatology (1989) [Pubmed]
  20. Non-ahr gene susceptibility Loci for porphyria and liver injury induced by the interaction of 'dioxin' with iron overload in mice. Robinson, S.W., Clothier, B., Akhtar, R.A., Yang, A.L., Latour, I., Van Ijperen, C., Festing, M.F., Smith, A.G. Mol. Pharmacol. (2002) [Pubmed]
  21. Hepatocarcinogenicity of hexachlorobenzene in rats and the sex difference in hepatic iron status and development of porphyria. Smith, A.G., Francis, J.E., Dinsdale, D., Manson, M.M., Cabral, J.R. Carcinogenesis (1985) [Pubmed]
  22. An inherited enzymatic defect in porphyria cutanea tarda: decreased uroporphyrinogen decarboxylase activity. Kushner, J.P., Barbuto, A.J., Lee, G.R. J. Clin. Invest. (1976) [Pubmed]
  23. Ligands specific to peripheral benzodiazepine receptors for treatment of porphyrias. Katz, Y., Weizman, A., Gavish, M. Lancet (1989) [Pubmed]
  24. Cytokeratin 8 protects from hepatotoxicity, and its ratio to cytokeratin 18 determines the ability of hepatocytes to form Mallory bodies. Zatloukal, K., Stumptner, C., Lehner, M., Denk, H., Baribault, H., Eshkind, L.G., Franke, W.W. Am. J. Pathol. (2000) [Pubmed]
  25. Effect of estradiol on the induction of porphyria by hexachlorobenzene in the rat. Legault, N., Sabik, H., Cooper, S.F., Charbonneau, M. Biochem. Pharmacol. (1997) [Pubmed]
  26. Thyroid function and thyroxine metabolism in hexachlorobenzene-induced porphyria. Kleiman de Pisarev, D.L., Rios de Molina, M.C., San Martin de Viale, L.C. Biochem. Pharmacol. (1990) [Pubmed]
  27. Cloning and expression of the defective genes from a patient with delta-aminolevulinate dehydratase porphyria. Ishida, N., Fujita, H., Fukuda, Y., Noguchi, T., Doss, M., Kappas, A., Sassa, S. J. Clin. Invest. (1992) [Pubmed]
  28. Familial porphyria cutanea tarda: characterization of seven novel uroporphyrinogen decarboxylase mutations and frequency of common hemochromatosis alleles. Mendez, M., Sorkin, L., Rossetti, M.V., Astrin, K.H., del C Batlle, A.M., Parera, V.E., Aizencang, G., Desnick, R.J. Am. J. Hum. Genet. (1998) [Pubmed]
  29. A mouse model of familial porphyria cutanea tarda. Phillips, J.D., Jackson, L.K., Bunting, M., Franklin, M.R., Thomas, K.R., Levy, J.E., Andrews, N.C., Kushner, J.P. Proc. Natl. Acad. Sci. U.S.A. (2001) [Pubmed]
  30. Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda. Bulaj, Z.J., Phillips, J.D., Ajioka, R.S., Franklin, M.R., Griffen, L.M., Guinee, D.J., Edwards, C.Q., Kushner, J.P. Blood (2000) [Pubmed]
  31. Toxicity of polychlorinated biphenyl with special reference to porphyrin metabolism. Sano, S., Kawanishi, S., Seki, Y. Environ. Health Perspect. (1985) [Pubmed]
  32. Iron removal therapy in porphyria cutanea tarda: phlebotomy versus slow subcutaneous desferrioxamine infusion. Rocchi, E., Gibertini, P., Cassanelli, M., Pietrangelo, A., Borghi, A., Pantaleoni, M., Jensen, J., Ventura, E. Br. J. Dermatol. (1986) [Pubmed]
  33. Thin layer chromatography and counter-current analysis in porphyrias. Aguadé, J.P., Herrero, C., Almeida, J., Smith, S.G., Belcher, R.V. Br. J. Dermatol. (1975) [Pubmed]
  34. Effect of thyroidectomy and thyroxine on hexachlorobenzene induced porphyria. Sopena de Kracoff, Y.E., Ferramola de Sancovich, A.M., Sancovich, H.A., Kleiman de Pisarev, D.L. J. Endocrinol. Invest. (1994) [Pubmed]
WikiGenes - Universities